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ABSTRACT
Introduction: Barriers to vaccination and the important role of healthcare professionals (HCPs) in
influencing immunization decisions made by parents/patients have been well documented. Little
information describes challenges that HCPs face in carrying out their role as vaccinators.
Methods: We conducted a focus group study asking HCPs to describe their expectations as frontline
vaccinators versus the day-to-day reality they faced. Participants described challenges impacting their
ability and motivation as vaccinators, and proposed key solutions to the most important challenges.
A total of 75 nurses and physicians (sixteen groups of frontline vaccinators) from the United Kingdom,
United States, Germany and India participated in 2 hour focus-group discussions.
Results: There was disconnect between how participants viewed their role in preserving population
health when they started their career, and the reality of real-world practice today. Challenges experi-
enced and reflected were similar across professional groups and countries. Low patient-level vaccine
knowledge, patient miseducation, untimely vaccine information, frequently changing vaccine schedules,
time pressures, lack of centralized record systems, pressure to achieve vaccination targets, and in some
instances vaccine costs, all impacted the efficiency and enthusiasm of HCPs. Identified solutions by the
same providers included improving patient-level information, equipping HCPs with effective informa-
tion, and practical ways to reduce the vaccination burden by improved administrative processes and
centralized recording coupled with delegating vaccinator roles.
Conclusion: This focus group gives unique insights into needs of HCPs to fulfill their role as vaccinators.
Supporting and equipping vaccinators is critical to the continuing success of vaccination programs and
the proposed life-course immunization strategy. (Supplementary Appendix 1)
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Introduction
Along with clean water, good nutrition and healthy sanitation
practices, vaccination is the mainstay of infectious disease
control.1 Vaccines arrive at their point of administration as
a result of decisions and actions involving numerous individuals
(or groups of individuals) who evaluate, recommend, procure,
distribute and oversee their availability. At the helm of admin-
istration, is the vaccinator (or vaccine provider), who is the
primary individual responsible for vaccination decisions.
The healthcare environment of the 21st century is markedly
different from the 1940–50s’when vaccines were first introduced
for routine use in universal immunization programs.1 The 21st
century vaccination landscape is characterized by unprecedented
access to information, rising levels of vaccine hesitancy among
patients and healthcare professionals (HCPs) such that vaccine
hesitance has been included in the top 10 threats to global health
by the World Health Organization,2 as well as increasing
requirements for efficiencies in healthcare delivery and docu-
mentation of healthcare interventions by HCPs. In the 21st
century, dozens of vaccines are available and their use in indivi-
dual countries may be mandated, recommended, or optional,
with large differences in the cost to patients across countries,
healthcare systems and insurance plans. By contrast, many of the
infectious diseases and their consequences that are targeted by
vaccination are rarely seen nowadays by physicians or the gen-
eral public. Vaccination schedules vary between and within
countries, and within populations (ie, recommendations for
individual vaccines can vary according to age or the presence
of risk factors). Vaccination schedules also change constantly as
new vaccines (and older vaccines with new indications) aremade
available, and as new information about effectiveness and safety
come to hand. Vaccines undergo rigorous and continuous test-
ing of quality, effectiveness and safety.3,4 Issues around vaccine
supply, safety, effectiveness and scheduling can arise at any time
and be rapidly disseminated across different media platforms. In
this way, frontline vaccinators can find themselves in situations
where their patient appears to be better informed than they are
about current vaccine issues. Furthermore, low levels of knowl-
edge has been associated with overconfidence amongst non-
professionals in their own knowledge.5
The frontline vaccinator remains the strongest influencer of
vaccine uptake by the general population,6–10 and is typically an
HCP who is committed to vaccinating and advocating
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vaccination. Numerous studies documenting the causes, effects
and extent of vaccine hesitancy have reiterated the need to equip
and educate frontline vaccinators in order to maintain high vac-
cine coverage.10 However, less is known about how vaccinators
viewed their role versus the reality of the vaccination administra-
tion experience. We conducted a qualitative study to investigate
perceived gaps between the expectations of HCPs in their role as
vaccinators and the reality of the world they operate in. Sixteen
groups of pediatricians, general practitioners and nurses who met
screening criteria to ensure that they worked actively as frontline
vaccinators were interviewed. Participants were from four coun-
tries representing different healthcare, insurance and reimburse-
ment systems; the United States (US), United Kingdom (UK),
Germany and India. We asked vaccinators about the challenges
they face over every part of the vaccination journey and for
practical solutions that would help revitalize their role.
Results
Sixteen groups that included a total of 75 nurse and physician
vaccinators from four countries, participated in individual
and focus group discussions in 2018 between October 16–27
in the US, Germany and the UK, and November 13–17 in
India. In the US, 10 pediatricians, 10 general practitioners/
family physicians (GPs) and 8 nurses were divided across six
groups, in the UK, 10 GPs and 10 nurses were divided into
four groups, in Germany, 9 pediatricians and 8 GPs were
divided into four groups, and, in India 10 pediatricians were
divided into two groups (Table 1).
The role of HCPs as vaccinators: expectations versus
reality
There was a significant disconnect between how participants
viewed their role as HCPs, and more specifically as vaccinators,
and the realities of real-world practice (Figure 1). The reasons
underlying this disconnection were similar across the different
professional groups and between individual countries. While
vaccinators were expected to have meaningful encounters with
patients, underwritten by continuity of care and a solid con-
viction by patients in the benefits of vaccination, the reality was
characterized by large administrative loads, constricting influ-
ences of regulations, rigid vaccination plans, and extensive time
spent educating and convincing parents to accept vaccination
associated with a sense of loss of trust, as illustrated during
interviews (Figure 2). HCPs expected immunization to be
a well-supported directive process, but the evolving reality is
a ‘battle’ against vaccine misinformation and substantial paper-
work. HCPs expressed feelings of guilt, frustration and disillu-
sionment due to the loss of patient centricity and the feeling
that they should be doing more for their patients. HCPs
reported that unexpectedly, vaccination episodes in clinical
practice were taking time away from other priorities because
of the increasing number of vaccinations available, and the
increasing time spent convincing patients of their value.
Country-specific findings on the role of HCPs
In addition to the common findings stated above, pediatri-
cians in Germany expected to receive support from the state
in terms of public vaccination campaigns. The reality was
heavy regulation from the insurance system and issues with
Table 1. Number of participants and focus group discussions.
United
States
6 groups
United
Kingdom
4 groups
Germany
4 groups
India
2 groups
Pediatricians 10
participants
– 9
participants
10
participants
General
Practitioners
10
participants
10
participants
8
participants
–
Nurses 8
participants
10
participants
– –
Figure 1. The role of vaccinator: expectations versus reality.
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parents delaying vaccines or splitting schedules. These chal-
lenges were also highlighted in the US. In the UK, pressure to
meet performance targets was highlighted as a key challenge.
In India, vaccine shortages and cost of vaccines were high-
lighted as an additional challenge.
Challenges faced as a vaccinator and solutions proposed
by HCPs
Vaccinators identified challenges during all stages of the vacci-
nation journey – from the background period prior to seeing
a patient, during the pre-vaccination consultation phase, admin-
istration process, and during the period after vaccination. The
overall and country-specific challenges are described below and
shown in Figure 3. These challenges had varying degrees of
impact on the ability of HCPs to be efficient and enthusiastic
vaccinators. Potential solutions identified by HCPs for some of
these challenges are provided below (Figure 4).
Challenges faced by all countries
During the pre-vaccination phase, “vaccination targets and
pressure to achieve them” was identified as a high impact
challenge. It detracted at times from HCPs’ ability to provide
expected standards of care, particularly with respect to reach-
ing targets for seasonal influenza and pneumococcal vaccines
for adults. HCPs indicated that this led to feelings of power-
lessness, reduced flexibility when consultations were focused
on reaching targets, and was seen as ultimately taking away
from provision of holistic care.
There is a growing move in some countries to “devolve
vaccination responsibilities from physicians and nurses to
pharmacists or non-medically qualified persons”. HCPs
acknowledged that sharing the vaccination load could reduce
practice workloads. On the other hand, this low-impact chal-
lenge during the pre-vaccination phase poses potential risks,
identified particularly by UK vaccinators (see below).
During the vaccination and post-vaccination phases, the
number one high-impact challenge in all countries, was the
problem of “little knowledge or misinformation about vac-
cines by parents/patients” (Figure 3). Patients/public present-
ing with a lot of information and misinformation available via
media (especially the Internet) required substantial time to
discuss/attempt to correct or reverse misinformation and con-
vince patients/parents to agree to vaccination. HCPs believed
that this time would be better spent seeing to other patient
needs. The potential solution proposed by HCPs was a multi-
faceted patient/public education approach to challenge vaccine
misinformation while providing patients with the information
they need to make informed decisions (Box 1).
HCPs and patients have an expectation that “sufficient time
will be available to discuss parent/patient questions and con-
cerns about vaccinations”. However, consultation times are
usually fixed and often restricted to 10–15 minutes, and ‘time’
was identified as a frequent and recurring high-impact vaccina-
tion phase challenge for HCPs, as more administrative
Figure 2. Healthcare provider opinions about the expectations versus reality of the vaccinator role.
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(including vaccine-related administrative requirements) and
logistical factors impacted on the consultation itself.
Consultation times are often based on the time needed to
address one health concern. When the patient record shows
that one or more vaccines are also required, HCPs must assess
the need to vaccinate at that appointment based on risk (expo-
sure to a preventable disease and likelihood of returning for
a second visit). HCPs expressed that time constraints and pres-
sures limited their effectiveness to provide best patient care.
Another high-impact vaccination/post-vaccination phase
challenge occurs “when patients move within a country or to
another country with incomplete records”. The absence of
centralized patient records leads to unnecessary use of consulta-
tion time to determine the vaccination history, and wasteful use
Figure 4. Challenges and some ideas to solve the issues expressed by healthcare providers.
Figure 3. Challenges faced by vaccinators at each stage of the vaccination process.
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of vaccines should patients need to be re-vaccinated “just in
case”. HCPs also noted that the mandatory processes by which
vaccinations must be recorded are complicated, and that the
vaccine administration itself was short in comparison to the
time required to record their administration. HCPs proposed
to reduce the logistic and practical burden via solutions that
improve the recording and sharing of patient record information
and administration processes (Box 2).
A medium-impact challenge during the vaccination/post-
vaccination phases in all countries was identified by pediatricians
and/or nurses commenting on the “ever-increasing number of
vaccinations required during childhood and adolescence”. The
frequency of vaccination conflicts with parents’ reluctance to
“inflict pain” during the first years of life, and requires additional
explanation and reassurance from HCPs. Parent reluctance to
administer multiple injections at the same visit increases the
logistical challenge for HCPs in ensuring that pediatric patients
receive all their vaccines in a timely manner. Patient records need
to be up to date and clear when vaccinations are due, in order to
remind parents at other appointments. This process is further
complicated if the patient is vaccinated by another HCP and this
administration is not included on medical records.
A low-impact challenge during the vaccination/post-
vaccination phases in all countries, was due to a growing
demand from patients for a ‘human touch’ during their consul-
tations, combined with a reduced tolerance for error. As a result,
HCPs are increasingly encouraging and administering vaccines
more cautiously in order to protect themselves from potential
“legal repercussions in the event of an unexpected outcome”.
The threat of legal proceedings negatively impacts on their
ability to be efficient and enthusiastic vaccinators.
Challenges in Germany
In the pre-vaccination phase, high impact challenges identi-
fied were “uncertainty surrounding current immunization
guidelines”, as well as “frequent changes to the immuniza-
tion schedule”, often occurring at short notice, creating
logistical and practical challenges in terms of identifying
which patients should be vaccinated. Some HCPs were not
sure where to access the most up-to-date vaccine guidance,
which added further time to the consultation. HCPs were
often left to justify changes to schedules to parents/patients
when someone once eligible, was no longer eligible under the
new recommendations. This led patients to question the
credibility of the need for vaccination. HCPs identified that
they need to be confident in delivering patient care and be
well equipped to answer questions and address objections
about vaccinations via HCP education and more flexible
guidelines (Box 3).
“Recurring vaccine stock shortages” was a medium-
impact pre-vaccination challenge. Vaccine shortages require
HCPs to risk-stratify individual patients, and reduces their
ability to provide all-round patient care. Explaining to
patients that they are of lower risk than others, and therefore
not able to be vaccinated during the shortage undermines the
importance of vaccination, which can be counter-productive
in an environment where patients are not always advocates of
vaccination.
A high-impact challenge during the vaccination and post-
vaccination phases included “poor timing of up-to-date vac-
cine information provided to HCPs”. GPs felt they were not
informed quickly enough about current vaccine issues. This
included the availability and recommendations for new vaccines,
changes to existing schedules, the most recent information
around side-effects, and new information arising from research
studies. HCPs felt they were at a disadvantage when faced with
patient questions, and were often in the situation where the
parent/patient appeared more informed (frequently incorrectly)
via the media than the HCPs conventionally informed via offi-
cial/professional channels.
A medium-impact challenge during the vaccination/post-
vaccination phase was due to increasing discussions with “parents
trying to design their own vaccine schedule” which may go
against recommendations and insurance requirements, thus
restricting HCPs’ capacity to immunize their patients
appropriately.
Box 1. Solution 1: A multi-faceted patient education approach to challenge vaccine misinformation while providing patients with the information they
need to make informed decisions, including:
● Providing general information via patient-directed information leaflets at each vaccination
● Surgery waiting room videos on the importance of vaccines and on local vaccine schedules
● Educating new parents during prenatal and antenatal contacts (seen as particularly relevant in Germany and the UK)
● Inclusion of vaccine education in the school health syllabus (seen as particularly relevant in India)
● Use of positive public vaccination health campaigns
● Television and radio campaigns advocating the importance of public immunization.
Box 2. Solution 2: Solutions to improve the recording and sharing of patient record information and streamline administration processes.
● Streamlined and centralized patient vaccination record system
● Make software available to conduct patient reminders/patient recall to complete required vaccination schedules (seen as particularly relevant in the US)
● Simplify communication between different HCPs involved in vaccines, and improve the timeliness of these communications
● Development and availability of more combination vaccines to reduce the number of injections required for infants and children
● Increased use of needle-less systems to ease the logistics of vaccine administration.
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Challenges in the UK
As was the case in Germany, in the pre-vaccination phase in the
UK, high impact challenges identified were “uncertainty sur-
rounding current immunization guidelines”, as well as “fre-
quent, often short notice, changes to the immunization
schedule”. As in Germany, this led to increased consultation
time and discussions with patients, with HCPs identifying solu-
tions in Box 3.
“What challenges me most is trying to make head or tail of the
shingles vaccination schedule. You’ve got who gets a turn, and in
which year, and why it has been planned out so ridiculously to
have different age groups every year? … the whole vaccine sche-
dule changes so rapidly from year to year.” UK nurse.
“Recurring vaccine stock shortages” was a medium-impact
pre-vaccination challenge that led to risk-stratification and selec-
tion of patients for vaccination, undermining the importance of
vaccination for the patient. Stock shortages currently impact
travel vaccines, but shortages of generally recommended vac-
cines have also occurred.
A low-impact pre-vaccination challenge was the “devolve-
ment/shared vaccination role with other HCPs”. UK HCPs
highlighted issues such as breaks in communication between
these other vaccinators and GPs resulting in a loss of continuity
of care and incomplete patient records. Concerns were expressed
by nurse vaccinators that other providers (such as pharmacists)
would not adhere to the same care practices nor engage in appro-
priate clinically relevant discussions with patients. HCPs also
questioned the logistics of managing vaccination targets if vaccine
responsibilities were shared. Box 4 outlines potential solutions to
obtain the most benefit from sharing the vaccinator role.
During the vaccination and post-vaccination phases,
“rapid provision of up-to-date vaccine information (e.g.,
new recommendations, schedules, side-effects) to HCPs”
was a high-impact challenge identified by GPs and nurses.
This resulted in problems when dealing with patient questions
that were often poorly-informed through the media.
Challenges in the US
A medium-impact challenge during the vaccination/post-
vaccination phase was due to “parents increasingly trying
to design their own vaccine schedule” based on decisions
made from their own research. These ‘a la carte’ schedules
may conflict with vaccination recommendations or insurance
requirements and they limit the ability of HCPs to effectively
immunize their patients. Discussions about parent-designed
schedules further extend the vaccination process.
Challenges in India
In the pre-vaccination phase in India, “uncertainty sur-
rounding current immunization guidelines” was a high
impact challenge, as was the “cost of vaccines”. Some of
the more recently implemented and more expensive vac-
cines, such as pneumococcal conjugate vaccines, are recom-
mended but not provided for free. Given the low incomes
of a large proportion of families in India, the affordability
of vaccines is a challenge for many. Furthermore, a general
lack of knowledge of the disease causes patients to question
the need for vaccines, especially given the (perceived) high
cost.
“Recurring vaccine stock shortages” was a medium-
impact pre-vaccination challenge that led to vaccination of
select patients according to risk. This decreases the value of
vaccination in patients’ eyes.
During the vaccination and post-vaccination phases, the
number one high-impact challenge faced by all countries, was
Box 4. Solution 4: Enable the sharing and development of the vaccination role across HCPs types to free up consultation time mainly through.
● Training of healthcare assistants to perform and provide information on vaccines to patients, to relieve general practitioners and pediatricians of this
role (seen as particularly relevant in the UK and Germany)
● Devolvement of a vaccination role to pharmacists (not favored by nurses)
● Delegate administration of all travel vaccines to independent travel vaccine centers.
Other lower priority suggestions:
● Put in place insurance company or government-based reward systems to encourage vaccinations (only considered important in Germany)
● Mandate the use of vaccines (seen as less relevant in the UK and of most relevance in India)
● Greater government involvement in vaccine campaigns to subsidize the cost of vaccines (only considered important in India).
Box 3. Solution 3: Ensure HCPs are confident in delivering patient care and feel well equipped to answer patient questions and address objections via HCP
education and more flexible guidelines.
● Access to transparent, reliable and timely vaccine information/education for HCPs, via:
○ Representatives (an important information source in the US, the UK and Germany)
○ Podcasts
○ Webinars (seen as particularly relevant in the US and the UK)
○ Forums for online peer discussions
○ Scientific congress presence by vaccine manufacturers with symposia and masterclasses (seen as particularly relevant in Germany)
○ E-mails (seen as less favorable by all participants).
● Provision of clear but flexible guidelines and targets (including insurance requirements in the US) that are compatible with the real-world healthcare
system. That is, affording HCPs more autonomy about which patients should or should not receive specific vaccines.
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the problem of “little knowledge or misinformation about
vaccines by parents/patients”. In India in particular, HCPs
were faced with a lack of general understanding about the
purpose of vaccines among sections of the population.
Discussion
Across all countries, HCPs expected, in their role as vaccinators,
to deal with a limited number of vaccines and to have the trust of
patients who accept the benefits of vaccination. The reality,
however, is that there are an increasing number of vaccines
with rigid vaccination plans and a lot of paperwork. The HCPs
often have to deal with misinformed anxious parents that ques-
tion the value of vaccination due to negative press. Specifically,
in Germany and the US, parents attempt to delay or modify
vaccine schedules while insurance companies exert additional
pressure through regulations. In India, vaccine shortages and
vaccine cost are issues, as are travel vaccine shortages in the UK.
In the 21st century, patient education/miseducation, often
obtained through the Internet and social media channels, has
emerged as one of the most important factors influencing vacci-
nation readiness in the real-world setting. In a survey of US
pediatricians and GPs published in 1994, vaccine cost and lack
of insurance coverage were among the most commonly identi-
fied barriers to vaccination.11 According to our survey, the issue
of vaccine cost continues to dominate in India where more
expensive pediatric, new maternal and adult vaccines are not
yet considered affordable by governments, and where substantial
differences exist in the vaccines supplied through the public
versus the private systems. In the US, UK and Germany, the
need to address patient misinformation coupled with associated
perceptions of loss of trust, contribute to a wide disconnect
between the role as vaccinator versus the reality of clinical
practice. In parallel, new vaccines, new indications, changes to
schedules and rapid global dissemination of vaccine information
have left someHCPs feeling poorly informed and ill-equipped to
address questions, concerns and misinformation coming from
parents/patients. These feeling are compounded by frustration
and feelings of inadequacy in being able to provide holistic
patient care within the timeframes available, and frustration
with the administrative processes involved.
There is a great deal of literature about vaccine confi-
dence or hesitancy among HCPs and how HCP confidence
correlates with coverage.6,10,12–16 Other studies examining
communication methods have highlighted parents’ needs
for impartial discussions about vaccines from HCPs, using
patient-tailored information.17–19 Much less is written about
the challenges HCPs themselves face in undertaking this
role. In our study, HCPs identified that patients’ low vac-
cine education/miseducation, untimely and/or unclear vac-
cine information, frequently changing vaccine schedules,
lack of time in consultations, lack of central patient record
systems, pressure to achieve vaccination targets, and vaccine
cost, all highly impacted their efficiency and enthusiasm.
These findings are consistent with other studies reporting
that HCPs frequently feel unprepared to discuss vaccine
issues, and that they face time constraints during vaccine
visits.6 Inability to track under-vaccinated patients and
incomplete immunization records were identified as key
barriers to immunization in a 1994 survey.11 These aspects
were also raised as high impact challenges in the present
study, suggesting that progress in this direction still needs
to be made. Unique insights from our study are the percep-
tion among some HCPs of loss of trust from their patients
with respect to vaccination, and the negative impact of
complex and changing vaccination schedules on HCPs’ abil-
ity to be effective vaccinators. Trust in vaccination is not
always specifically evaluated.20 The causes of reduced
patient trust and the impact on HCPs have not, to our
knowledge, been explored. The negative impact of rapidly
changing and complex vaccination schedules on vaccinators
has also perhaps been underestimated.21 Health authorities
often attempt to contain costs by limiting access to subsi-
dized vaccines to those most at risk, or by rolling out
vaccination campaigns to different age groups over conse-
cutive years. However, the frontline vaccinator is left to
explain these strategies to patients, on the one hand trying
to advocate vaccination, and on the other having to explain
to patients/parents why one individual is eligible for vacci-
nation, while another is not. These apparent inconsistencies
potentially risk undermining vaccination as a whole.
Focus groups are a complementary tool to other scientific
research that can provide nuanced insights into real-world
experiences. In this study, dynamic discussions within small
groups of vaccinators allowed deep insights into their per-
ceived versus actual roles, and encouraged their expression of
challenges and proposed solutions based on their experiences
as real-world vaccinators. Findings from this survey may
stimulate reflection on why vaccination practice is not as
smooth as expected and help identify solutions that can be
integrated into daily practice.
The solutions identified by HCPs centered around improv-
ing the quality of patient information, better equipping HCPs
with the information they need to be effective vaccinators and
vaccine advocates. As a last solution, HCPs highlighted the
need to reduce the workload associated with vaccination by
improving administrative processes and centralized recording,
plus possibly devolving vaccinator roles. Study participants
stressed that HCP and patient-focused communication and
education must be seen to be ‘independent’, free from bias,
and easily accessible. Solutions involving changes to national
healthcare systems/processes should be approached as long-
term commitments, and require substantial investment and
resources to overcome potential bureaucratic and legal
barriers.
Strengths of the survey are the inclusion of vaccinators
from a variety of healthcare backgrounds from developed
countries and a developing country. The four countries repre-
sented different healthcare systems, which increases the trans-
ferability of our insights to other settings. Limitations include
the small sample size, convenience sampling methodology and
the “one-off” nature of the survey.
Frontline vaccinators are the most important influencers of
vaccine uptake by the general population.6–10 However, HCPs
expectations of their role as vaccinators are not matched with
reality. This experience extends across professions and coun-
tries. Education and information campaigns for patients and
HCPs will address the challenges that have the highest impact
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on vaccinators: those of poor patient education and unclear/
untimely HCP-directed information. Solutions which look to
establish clear guidelines and to streamline and centralize the
patient record system processes will address challenges that
exist across multiple stages of the vaccination journey.
Supporting and equipping vaccinators is critical to the con-
tinuing success of vaccination programs and the proposed
life-course immunization strategy.
Methods
Through focus groups, a qualitative market research survey fol-
lowing a social constructivism perspective was conducted and
a non-probability method of convenience sampling was adopted.
Country-specific group selection
The four study countries (US, UK, Germany and India), were
selected to provide views from HCPs working in very different
vaccine administration environments. In the US, vaccines are
usually administered by physicians (mainly pediatricians) while
nurses have a key role in terms of providing advice, guidance and
preparing patients for vaccination. Non-physician HCPs, such as
medical/physician assistants, nurses and pharmacists can be
authorized to administer vaccines according to laws that vary at
a state-by-state level.22 The cost of vaccines varies according to
insurance status, but are free for those eligible for the Vaccines for
Children Program.23 In the UK, vaccines recommended by the
National Health Service (NHS) are free of charge to families,24 and
vaccines are primarily administered by nurses and general practi-
tioners. In Germany, vaccines are given by private physicians or
general practitioners in their offices.25,26 Vaccines recommended
by the German Standing Vaccination Committee (STIKO) are
available free of charge through the statutory insurance policy.24
In India, most vaccines recommended by the Indian Academy of
Pediatrics (IAP) are provided free of charge.27 However, some
vaccines such as pneumococcal conjugate vaccines and acellular
pertussis vaccines are only available through the private sector.
This holds true for maternal vaccination (other than the conven-
tional tetanus toxoid), and those vaccines recommended for adults
and older age groups as part of the life-course approach. This,
combined with a perception among some parents that interna-
tionally manufactured vaccines may be more effective than locally
made products, means that many parents opt to be vaccinated
through the private sector.
The research was conducted by an independent market
research company (Cello Health Insight). Potential participants
were contacted by telephone or email from databases of HCPs
held by the company and their locally-based suppliers. HCPs
were screened using a standardized form (Supplementary
Appendix 2) to ensure the vaccinators selected from each coun-
try were representative of that role in the region, thus able to
reflect frontline concerns and challenges.
To be eligible to participate, HCPs had to spend 70% of more
of their time in direct patient care; have been in practice between
3 and 30 years; have administered and/or recommended/per-
sonally discussed measles-mumps-rubella/varicella and
diphtheria-tetanus-pertussis-containing pediatric vaccines with
patients in the last 3 months; and been involved in the
administration/prescribing of vaccines or responsible for dis-
cussing vaccine options and making recommendations to
adults/adolescents/children. GPs and nurses were additionally
required to have recommended/personally discussed at least two
adult and/or travel vaccines with patients in the last 3 months.
Participants could not have participated in vaccination-
related market research in the last month. HCPs (or their family
members) affiliated with any pharmaceutical company, health-
care manufacturer or market research company, were not eligi-
ble to participate. In the US, HCPs could not participate if they
were a government employee or if they were licensed to pre-
scribe medications or practice/work in a medical capacity in
Vermont or Minnesota. All US participants had to be board
certified or board eligible in their specialty. Half of the US
participants were selected from independent practices (outpati-
ent practice with single site), and the other half from an
Integrated Delivery Network (outpatient practice with multiple
sites, hospital-based practice or health systems headquarters).
A quota was set in terms of the number of participants and
HCP type in each country. All participants were offered
financial reimbursement for their participation in the 2 hour
group discussion.
Survey description
Two hour one-to-one and group discussions were undertaken to
gain insights into the understanding HCPs have of their role as
vaccinators and to identify the challenges they face in this role.
All sessions were facilitated by an experienced researcher from
the market research company. All participants provided written
consent to participate and the study sponsor was not disclosed to
participants. Anonymity of the participants was maintained
during video recordings and in transcripts of the meetings.
Analysis
Individual and focus group responses were analyzed following
narrative analysis principles (including word and phrase repeti-
tions). We conducted a detailed local language analysis of the
recordings followed by a thematic analysis performed by experi-
enced specialist healthcare researcher through
a phenomenological lens. Key themes were identified and dis-
cussed to ensure consistency. The analysis was conducted in
a precise, consistent, and exhaustive manner in order to guide
appropriate interpretation and identification of key data points.
Data were analyzed according to profession-specific and country-
specific information disclosed through the survey. The study
adhered to standards for reporting qualitative research (SRQR)
guidelines.28
Ethics approval
This was a market research activity and no ethics approval
was sought.
Ethical considerations for focus groups, as for other social
research methods, involve informing potential participants of the
purpose of the research, and how their contribution will be used,
how sensitive material and confidentiality will be handled (clarify
that participants contributions will be shared with others in the
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group and that data will be anonymized).29 In this study, written
consent was obtained from all participants (a screener was used to
provide extensive information about the study, inform potential
participants about confidentiality and anonymity of results,
inform them that the sponsor was a pharmaceutical company
but that the research is non-promotional, allow the potential
participants to accept or decline participation at several points).
The study is compliant to general data protection regulation and
adheres to standards and techniques for healthcare market
research EpHMRA and BHBIA guidelines. Experienced research-
ers facilitated all the focus groups, the sponsor was not disclosed
and anonymity of participants was maintained throughout.
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